Patient with lung metastases of malignant melanoma who have long-term survival in combination therapy BRAF and MEK inhibitors

Abstract

Targeted treatment of BRAF and MEK inhibitors and targeted antibody treatment against immune response checkpoints showed a significant advance in the treatment of generalized malignant melanoma against previously used chemotherapy and radiotherapy. The results of the clinical studies confirmed a markedly higher response rate and an increase in overall survival in patients treated with both types of this medications.

Keywords

• melanom
• imunoterapie
• BRAF inhibitor
• MEK inhibitor